Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 36 points (0.2%) at 17,520 as of Thursday, Nov. 6, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,530 issues advancing vs. 1,416 declining with 183 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. Top gainers within the industry include

Envision Healthcare Holdings

(

EVHC

), up 4.5%,

Quest Diagnostics

(

DGX

), up 2.2%,

Agilent Technologies

(

A

), up 1.9%,

Grifols

(

GRFS

), up 1.9% and

Edwards Lifesciences

(

EW

), up 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Smith & Nephew

(

SNN

) is one of the companies pushing the Health Services industry lower today. As of noon trading, Smith & Nephew is down $0.60 (-1.8%) to $33.62 on light volume. Thus far, 92,187 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 386,400 shares. The stock has ranged in price between $33.45-$33.94 after having opened the day at $33.75 as compared to the previous trading day's close of $34.22.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.1 billion and is part of the health care sector. Shares are up 19.2% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Smith & Nephew

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Smith & Nephew Ratings Report

TST Recommends

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Brookdale Senior Living

(

BKD

) is down $0.66 (-2.0%) to $33.10 on heavy volume. Thus far, 1.4 million shares of Brookdale Senior Living exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $32.79-$34.27 after having opened the day at $33.63 as compared to the previous trading day's close of $33.76.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates in six segments: Retirement Centers, Assisted Living, Continuing Care Retirement Communities (CCRCs) Rental, CCRCs Entry Fee, Brookdale Ancillary Services, and Management Services. Brookdale Senior Living has a market cap of $5.9 billion and is part of the health care sector. Shares are up 24.2% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Brookdale Senior Living a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Brookdale Senior Living

as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full

Brookdale Senior Living Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Covidien

(

COV

) is down $0.49 (-0.5%) to $92.83 on light volume. Thus far, 1.3 million shares of Covidien exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $92.70-$93.50 after having opened the day at $93.50 as compared to the previous trading day's close of $93.32.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $41.6 billion and is part of the health care sector. Shares are up 37.0% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Covidien a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates

Covidien

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Covidien Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health services industry could consider

ProShares Ultra Short Health Care

(

RXD

).

null